-transparent.png){kind=logo}
Leflunomide is a novel drug recently introduced for treatment of rheumatoid arthritis as a DMARD (disease-modifying antirheumatic drug). So far, leflunomide has not been associated with severe bone marrow toxicity and pancytopenia. We report of a 62-year-old woman with a 14-year history of rheumatoid arthritis with bone marrow toxicity and reversible pancytopenia developing after treatment with leflunomide.
Related Publications
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
January 2007,
Modern rheumatology,
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
August 2012,
International journal of rheumatic diseases,
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
July 2006,
Rheumatology (Oxford, England),
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
September 2002,
Annals of the rheumatic diseases,
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
January 2008,
Clinical and experimental rheumatology,
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
July 2000,
Drug and therapeutics bulletin,
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
January 2002,
The Annals of pharmacotherapy,
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
May 1999,
Lancet (London, England),
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
May 1999,
Lancet (London, England),
J Auer, and
M Hinterreiter, and
S Allinger, and
A Kirchgatterer, and
P Knoflach
January 2003,
The Cochrane database of systematic reviews,
